Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11051363 | 0.86 | THRB (0.32) | THRBLMNA | |
| SCHEMBL11393229 | 0.85 | THRB (0.35) | THRBLMNA | |
| SCHEMBL613969 | 0.79 | — | — | |
| SCHEMBL22605512 | 0.79 | — | — | |
| SCHEMBL4192052 | 0.79 | — | — | |
| SCHEMBL9684403 | 0.75 | HTT (0.39) | — | |
| SCHEMBL19449202 | 0.75 | — | — | |
| SCHEMBL17304851 | 0.75 | — | — | |
| SCHEMBL31278963 | 0.73 | THRB (0.42) | THRBLMNA | |
| SCHEMBL3267702 | 0.72 | THRB (0.36) | THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112645391-B | Surface fluorination treatment method for lithium-containing metal oxide and application thereof | 浙江工业大学 | 2022-12-27 | — | — | CN | claimed |
| US-6833468-B2 | Reacting an optically active imine with a compound that is a hemiacetal of a perfluoroalkylaldehyde or a hydrate of a perfluoroalkylaldehyde to obtain a condensate, hydrolyzing | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-12-21 | — | — | US | claimed |
| CN-112645391-B | Surface fluorination treatment method for lithium-containing metal oxide and application thereof | 浙江工业大学 | 2022-12-27 | — | — | CN | disclosed |
| EP-2831042-B1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | INTERVET INT BV (NL) | 2019-07-31 | — | — | EP | disclosed |
| EP-2621923-B1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INT BV (NL) | 2017-03-29 | — | — | EP | disclosed |
| EP-2621903-B1 | N-HETEROARYL COMPOUNDS | INTERVET INT BV (NL) | 2017-03-01 | — | — | EP | disclosed |
| US-9321724-B2 | Heteroaryl compounds with A-cyclic bridging unit | INTERVET INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150057279-A1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | INTERVET INC. | 2015-02-26 | — | — | US | disclosed |
| EP-2831042-A1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | Intervet International B.V. (NL) | 2015-02-04 | — | — | EP | disclosed |
| US-8883791-B2 | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases | INTERVET INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8877934-B2 | N-heteroaryl compounds | INTERVET INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | INTERVET INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2012041873-A1 | N-HETEROARYL COMPOUNDS | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041872-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| US-6833468-B2 | Reacting an optically active imine with a compound that is a hemiacetal of a perfluoroalkylaldehyde or a hydrate of a perfluoroalkylaldehyde to obtain a condensate, hydrolyzing | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-12-21 | — | — | US | disclosed |
| US-6642409-B2 | Reacting an imine with a hemiacetal; hydrolysis under acid conditions | CENTRAL GLASS COMPANY, LIMITED (JP) | 2003-11-04 | — | — | US | disclosed |
| US-6639100-B2 | Baeyer-Villiger oxidation of an optically active 4,4,4-tri-fluoro-3-hydroxy-1-aryl-1-butanone; purification by precipitation and removing racemic crystals; agriculture; drugs; ferroelectric liquid crystals; chemical intermediates | CENTRAL GLASS COMPANY, LIMITED (JP) | 2003-10-28 | — | — | US | disclosed |
| US-20030100767-A1 | Reacting an optically active imine with a compound that is a hemiacetal of a perfluoroalkylaldehyde or a hydrate of a perfluoroalkylaldehyde to obtain a condensate, hydrolyzing | CENTRAL GLASS COMPANY, LIMITED | 2003-05-29 | — | — | US | disclosed |
| US-20030088095-A1 | Reacting an optically active imine with a hemiacetal of a perfluoroalkylaldehyde or a hydrate; hydrolyzing the condensate under an acid condition. | CENTRAL GLASS COMPANY, LIMITED | 2003-05-08 | — | — | US | disclosed |
| US-20020016511-A1 | Reacting an imine with a hemiacetal; hydrolysis under acid conditions | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057279-A1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | AADAC, PIGS, MTCL3 | THRB 4560/4885LMNA 1595/4885 |
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | HNMT, SQLE, PIGO | THRB 4491/4885LMNA 1785/4885 |
| US-20030100767-A1 | Reacting an optically active imine with a compound that is a hemiacetal of a perfluoroalkylaldehyde or a hydrate of a perfluoroalkylaldehyde to obtain a condensate, hydrolyzing | ADH1C, ADH1A, HPD | THRB 910/4885LMNA 888/4885 |
| US-20030088095-A1 | Reacting an optically active imine with a hemiacetal of a perfluoroalkylaldehyde or a hydrate; hydrolyzing the condensate under an acid condition. | ADH1C, ADH1A, HPD | THRB 1089/4885LMNA 785/4885 |
| US-20020016511-A1 | Reacting an imine with a hemiacetal; hydrolysis under acid conditions | ADH1C, ADH1A, HPD | THRB 924/4885LMNA 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.